Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...
After hours: March 24 at 4:05:11 PM EDT Loading Chart for MET-PE ...
After hours: March 21 at 7:53:41 PM EDT Loading Chart for MET ...
Bonus May 10, 2018 May 12, 2018 Mar 19, 2018 Bonus Ratio: 1 share(s) for every 20 shares held Bonus Nov 10, 2017 Nov 13, 2017 Jun 12, 2017 Bonus Ratio: 1 share(s) for every 20 shares held Gala Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback